Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hakim Hadana"'
Autor:
Ulrich Mentzel, Markus Kramberg, Marc Iglarz, Enrico Vezzali, Frederic Trensz, Céline Bortolamiol, Daniel Wanner, Stephane Delahaye, Hakim Hadana, Daniel S. Strasser, Patrick Hess, Markus Rey, Joël Ménard, Martine Clozel
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 368:462-473
The endothelin (ET) system has emerged as a novel target for hypertension treatment where a medical need persists despite availability of several pharmacological classes, including renin angiotensin system (RAS) blockers. ET receptor antagonism has d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d32d8d86285b9758185f4b07108c406
https://doi.org/10.1124/jpet.118.253864
https://doi.org/10.1124/jpet.118.253864
Autor:
Enrico Vezzali, Magali Vercauteren, Manuela Schläpfer, Céline Bortolamiol, Stephane Delahaye, Edgar Weber, Hakim Hadana, Marc Iglarz, Kyle Landskroner, Markus Rey, Brian R. Whitby, Daniel Wanner, Patrick Hess, Oliver Nayler, Christophe Cattaneo, Diego Freti, Pauline Steiner, Martine Clozel, Rolf Studer, Bérengère Renault, Yasmina Bauer
Publikováno v:
Journal of Cardiovascular Pharmacology
Supplemental Digital Content Is Available in the Text.
Aims: We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model o
Aims: We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbadfe07472519ec9813e1e3eeaaed66
https://pubmed.ncbi.nlm.nih.gov/26230396
https://pubmed.ncbi.nlm.nih.gov/26230396
Autor:
Marina Dos Santos, Daniel Ritz, Verena Kaegi, Azely Mirre, Maria Weiss, Stéphanie Kraemer, Daniel Bur, Michel Enderlin-Paput, Jean-Christophe Gauvin, Hakim Hadana, Georg Rueedi, Thierry Bruyère, Christian Hubschwerlen, Peter Seiler, Mika Gaertner, Jonathan Delers, Christopher Kohl, Wolfgang Keck, Jean-Philippe Surivet, Hans H. Locher, Patrick Hess, Eric A. Ertel, Cornelia Zumbrunn, Romain Sube
Publikováno v:
Journal of medicinal chemistry. 58(2)
Novel antibacterial drugs that are effective against infections caused by multidrug resistant pathogens are urgently needed. In a previous report, we have shown that tetrahydropyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e943cd2f129c2bf098a7a5867bb79e41
https://pubmed.ncbi.nlm.nih.gov/25494934
https://pubmed.ncbi.nlm.nih.gov/25494934